Previous 10 | Next 10 |
home / stock / lbtsf / lbtsf news
Almirall S.A. (ALM) today announced results from a new secondary analysis from the Phase 3 clinical development program which showed patients receiving lebrikizumab who were assessed at 16 weeks experienced improved or cleared face or hand dermatitis, which can be particularly burdensome and ...
Almirall, S.A. (LBTSF) Q4 2022 Earnings Conference Call February 20, 2023, 04:00 AM ET Company Participants Pablo Divasson Fraile - Director of IR and Corporate Communications Carlos Gallardo - Chairman & Interim CEO Karl Ziegelbauer - Chief Scientific Officer ...
Almirall, S.A. press release ( OTCPK:LBTSF ): FY Revenue of €863.2M (+4.4% Y/Y). Total EBITDA reached €198.3M, a 15.8% Y/Y decrease. Almirall closed 2022 with a healthy balance sheet and solid liquidity position at 0.8x Net Debt to EBITDA. Core Gross Margin ...
Almirall closes 2022 with a Core Net Sales growth of 6.6%, driven by its European Dermatology Business Almirall consolidates its position in Europe. The Dermatology business in this continent grew 18.4% year-on-year, boosted by new launches Almirall achieved its guidance for 202...
Carlos Gallardo, Chairman of Almirall, will represent the company in a session scheduled at 9am Pacific Standard Time on January 10 th , 2023 Almirall, S.A. (ALM) , a global biopharmaceutical company focused on skin health, today announced that it will participate in the u...
FACILITATE aims to create a framework for clinical trial participant’s data access and reutilisation for a fully transparent and ethical ecosystem Almirall brings its experience in privacy matters and pharmaceutical law, as well as in the development of guidance, ...
Almirall, S.A. (LBTSF) Q3 2022 Earnings Conference Call November 10, 2022 04:00 AM ET Company Participants Pablo Divasson del Fraile - Director of Investor Relations, Shareholders & ESG Carlos Gallardo - Chairman & Interim Chief Executive Officer Mike McC...
The following slide deck was published by Almirall, S.A. in conjunction with their 2022 Q3 earnings call. For further details see: Almirall, S.A. 2022 Q3 - Results - Earnings Call Presentation
Almirall, S.A. press release ( OTCPK:LBTSF ): Q3 Non-GAAP EPS of €0.18. Revenue of €633.8M (+5.3% Y/Y). For further details see: Almirall, S.A. Non-GAAP EPS of €0.18, revenue of €633.8M
Summary Beijing YishengBio will merge with a SPAC vehicle, Summit Healthcare Acquisition, to list on the Nasdaq Exchange at a pre-money equity value of $834 million. Simcere Pharma of Nanjing announced a $507 million out-licensing to Spain’s Almirall for ex-China rights to ...
News, Short Squeeze, Breakout and More Instantly...
Almirall Sa Ord Company Name:
LBTSF Stock Symbol:
OTCMKTS Market:
Almirall’s sustainability strategy focuses on five pillars: Planet, People, Patients, Partners and Principles defining clear targets and measurements Among other commitments, Almirall aims to – by 2030 - reduce absolute direct greenhouse gas emissions by 50%, minimize the ge...
Almirall presented the interim Week 52 results of the POSITIVE clinical study at the IFPA Conference 2024, showing the benefits of the effective treatment with Ilumetri (tildrakizumab) in patients with moderate to severe psoriasis achieving improvement of physical symptoms and overall wellbeing. ...
Positive trajectory with Net Sales increase by 6.6% to a total of €247.4 MM, EBITDA increase of 1.4% YoY to a total of €52.5 MM driven by higher overall sales Performance driven by biologics as key growth engines, with Ilumetri ® showing 30% increase in sales vs Q1 ...